MCF-7 Specific Neutra™ Antibody Products

Struggling with prolonged drug development timelines or inconsistent antibody performance in breast cancer research? Creative Biolabs' MCF-7 specific Neutra™ antibodies leverage advanced hybridoma technology and epitope-specific engineering to deliver high-affinity, validated reagents that accelerate therapeutic discovery and ensure reproducible results.

Introduction to the MCF-7 Breast Cancer Cell Line

The MCF-7 breast cancer cell line, established in 1973 from a metastatic pleural effusion of a postmenopausal patient, remains a cornerstone model for studying estrogen receptor (ER)-positive luminal breast cancer. As a hormone-sensitive line, MCF-7 expresses ERα, progesterone receptor (PR), and low levels of HER2, making it indispensable for investigating endocrine therapies, drug resistance mechanisms, and cancer cell proliferation pathways. Its genomic stability and well-characterized phenotypic traits underpin its utility in both basic research and preclinical drug screening.

• Structural Features

MCF-7 cells exhibit distinct membrane and intracellular structural components critical for their oncogenic behavior. Surface markers like ERα and HER2 dimerize upon ligand binding, activating downstream signaling cascades. Intracellularly, the overexpression of anti-apoptotic proteins (e.g., Bcl-2) and cyclin D1 drives uncontrolled proliferation. The unique architecture of MCF-7-derived xenografts, including dense tumor stroma and vascularization, closely mirrors clinical tumors, enabling translational studies.

• Key Signaling Pathways

MCF-7 proliferation and survival are orchestrated by ERα-mediated pathways, where ligand-activated ERα binds DNA to upregulate genes like CCND1 (cyclin D1) and MYC. Cross-talk with growth factor pathways—such as EGFR/HER2—amplifies MAPK/ERK and PI3K/AKT activation, promoting therapy resistance. Additionally, TGF-β signaling in MCF-7 modulates epithelial-mesenchymal transition (EMT), facilitating metastatic potential.

Fig.1 IGF-1 and TGF-β1 signaling in MCF-7 breast cancer cells.¹

• Associated Pathologies

MCF-7 is directly linked to luminal A breast cancer, the most common ER-positive subtype. This malignancy is characterized by hormone-driven growth, metastasis to bone and liver, and eventual resistance to aromatase inhibitors. Targeting MCF-7-specific markers is critical for developing therapies to counteract relapse and improve survival rates.

Applications of MCF-7 Neutralizing Antibodies

• Therapeutic Development

Anti-MCF-7 antibodies are pivotal in designing precision therapies. ERα-neutralizing antibodies reverse drug resistance by degrading unliganded receptors, while HER2-targeted agents synergize with drug to suppress metastatic growth. Preclinical studies show antibody-drug conjugates (ADCs) reduce tumor volume by 70% in xenograft models.

• Diagnostic Tools

High-specificity antibodies enable precise detection of MCF-7-derived circulating tumor cells (CTCs) in liquid biopsies, with sensitivity thresholds of 1 CTC per 7.5 mL blood. These tools are critical for early recurrence monitoring and patient stratification in clinical trials.

• Mechanistic Research

Antibodies against MCF-7 surface markers facilitate live-cell imaging to study receptor internalization dynamics or co-culture systems to evaluate immune cell infiltration. Neutralizing ERα in 3D spheroid models replicates therapy-resistant microenvironments, aiding compound screening.

Our Anti-MCF-7 Antibodies

Anti-MCF-7 neutralizing antibodies are engineered to bind ERα, HER2, or cell-surface glycoproteins (e.g., CD24), disrupting oncogenic signaling. For example, ERα-specific antibodies block ligand-binding domains, preventing genomic activation and inducing receptor degradation. HER2-targeted antibodies inhibit dimerization, suppressing PI3K/AKT-driven survival. These antibodies are rigorously validated for applications such as flow cytometry (detecting <1% antigen-positive cells), immunohistochemistry (tissue specificity ≥98%), and functional assays (IC₅₀ values ≤10 nM).

Creative Biolabs' MCF-7 specific Neutra™ antibodies provide researchers with high-specificity, rigorously validated tools to accelerate breakthroughs in breast cancer therapeutics and diagnostics.

Contact our team today to discuss your project requirements and explore how our antibodies can elevate your research outcomes.

REFERENCE

1. Walsh, Logan A., and Sashko Damjanovski. "IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition." Cell Communication and Signaling 9.1 (2011): 10. Distributed under Open Access license CC BY 2.0, without modification. https://doi.org/10.1186/1478-811X-9-10